IMPORTANT SHAREHOLDER ALERT: Khang & Khang LLP Announces an Investigation of Amphastar Pharmaceuticals, Inc. & Encourages Inv...
December 30 2016 - 1:38PM
Business Wire
Khang & Khang LLP (the “Firm”) announces that it is
investigating claims against Amphastar Pharmaceuticals, Inc.
(“Amphastar” or the “Company”) (Nasdaq: AMPH) concerning possible
violations of federal securities laws.
If you purchased shares of Amphastar and want more information
free of charge, please contact Joon M. Khang, Esquire, of Khang
& Khang, 18101 Von Karman Avenue, 3rd Floor, Irvine, CA 92612,
by telephone: (949) 419-3834, or by e-mail at
joon@khanglaw.com.
Amphastar announced that its company Armstrong Pharmaceuticals,
Inc. ("Armstrong") received notice from the U.S. Food and Drug
Administration ("FDA"), revealing to Armstrong that its New Drug
Application for Primatene Mist, an epinephrine inhalation aerosol
product, would not be approved. The FDA encouraged Armstrong to
implement changes to the product's label and packaging. The FDA
also suggested that Armstrong complete another Human Factor
validation study to assess client ability to use the product
independently of a doctor or pharmacist.
When this information was revealed to the public, the value of
Amphastar fell, causing investors harm.
If you have any questions concerning this notice or your rights,
please contact Joon M. Khang, a prominent litigator for almost two
decades, by telephone: (949) 419-3834, or by e-mail at
joon@khanglaw.com.
This press release may constitute Attorney Advertising in some
jurisdictions.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20161230005259/en/
Khang & Khang LLPJoon M. Khang, Esq.Telephone:
949-419-3834Facsimile: 949-225-4474joon@khanglaw.com
Amphastar Pharmaceuticals (NASDAQ:AMPH)
Historical Stock Chart
From Aug 2024 to Sep 2024
Amphastar Pharmaceuticals (NASDAQ:AMPH)
Historical Stock Chart
From Sep 2023 to Sep 2024